Search research articles
Contact Us
Filters
Showing results (51-60 of 56) with videos related to
Page
of 6
Sort By:
You have reached the last page of results.
This site can display upto 56 results.
International Journal of Cancer
|
October 11, 2017
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
Valerie Heong, Nicholas L Syn, Xiao Wen Lee, et al.
The Lancet. Oncology
|
January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
Natalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
International Journal of Molecular Sciences
|
July 2, 2021
Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
Hweixian Leong Penny, Je Lin Sieow, Sin Yee Gun, et al.
Frontiers in Oncology
|
October 11, 2021
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives
Sneha Rajiv Jain, Wilson Sim, Cheng Han Ng, et al.
Nature Medicine
|
November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine
|
September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Page
of 6
Search research articles
Search
Showing results (51-60 of 56) with videos related to
Sort By:
Page
of 6
You have reached the last page of results.
This site can display upto 56 results.
International Journal of Cancer
|
October 11, 2017
Value of a molecular screening program to support clinical trial enrollment in Asian cancer patients: The Integrated Molecular Analysis of Cancer (IMAC) Study
Valerie Heong, Nicholas L Syn, Xiao Wen Lee, et al.
The Lancet. Oncology
|
January 18, 2026
Pembrolizumab plus lenvatinib in recurrent gynaecological clear cell carcinoma (LARA): a multicentre, single-arm, phase 2 trial
Natalie Y L Ngoi, Jung-Yun Lee, Diana Lim, et al.
International Journal of Molecular Sciences
|
July 2, 2021
Targeting Glycolysis in Macrophages Confers Protection Against Pancreatic Ductal Adenocarcinoma
Hweixian Leong Penny, Je Lin Sieow, Sin Yee Gun, et al.
Frontiers in Oncology
|
October 11, 2021
Statistical Process Control Charts for Monitoring Next-Generation Sequencing and Bioinformatics Turnaround in Precision Medicine Initiatives
Sneha Rajiv Jain, Wilson Sim, Cheng Han Ng, et al.
Nature Medicine
|
November 20, 2025
Editorial Expression of Concern: Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Nature Medicine
|
September 1, 2014
Rationale for co-targeting IGF-1R and ALK in ALK fusion-positive lung cancer
Christine M Lovly, Nerina T McDonald, Heidi Chen, et al.
Page
of 6